TickerFacts.

Perspective Therapeutics, Inc. (CATX): Long-Term Debt

Annual figures by period end, from SEC filings.

$1.62M
As of 2025-12-31
$1.60M
As of 2026-06-30
$1.73M2023-12-31: $1.73M2024-12-31: $1.68M2025-12-31: $1.62M$1.62M
2023-12-31 Long-Term Debt (USD) 2025-12-31
Period endedLong-Term DebtChange YoYSource filing
2025-12-31$1.62M-3.1%2026-03-16, Balance as of period end
2024-12-31$1.68M-2.8%2025-03-28, Balance as of period end
2023-12-31$1.73Mn/a2024-03-28, Balance as of period end

Long-Term Debt at similar companies

Companies with the same SEC industry code (Pharmaceutical Preparations), reporting in the same currency, closest in revenue. Each shows its own latest fiscal year, so period ends differ.

CompanyYear endedLong-Term DebtChange YoY
Perspective Therapeutics, Inc. (CATX)2025-12-31$1.62M-3.1%
Phathom Pharmaceuticals, Inc. (PHAT)2025-12-31$209.09M+3.8%
Tonix Pharmaceuticals Holding Corp. (TNXP)2024-12-31$8.65M-21.4%
Altimmune, Inc. (ALT)2025-12-31$34.29Mn/a
Savara Inc (SVRA)2025-12-31$29.91M+12.4%
Zevra Therapeutics, Inc. (ZVRA)2025-12-31$61.93M+4.1%
Verastem, Inc. (VSTM)2024-12-31$40.72M+1.6%
BioAge Labs, Inc. (BIOA)2024-12-31$8.50Mn/a
Lifecore Biomedical, Inc. (LFCR)2025-05-25$130.44M+4.6%

Compare CATX, PHAT, TNXP, ALT side by side · Screen every company in Pharmaceutical Preparations ↗